Physician profile
John Cribb
NPI 1265526891
$5,563.95
in general payments reported to CMS, 2019-2025
26 companies · $1,511 in 2025
The $1,511 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $169 · 2021: $292 · 2022: $608 · 2023: $1,040 · 2024: $1,471 · 2025: $1,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,022.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,517.95 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $571.34 | 2019-2025 | Xifaxan |
| Ardelyx, INC. | $425.79 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $315.45 | 2023-2025 | Voquezna |
| Celgene Corporation | $259.13 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $188.22 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $176.68 | 2022-2024 | Dupixent |
| Genzyme Corporation | $164.52 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $151.45 | 2019-2024 | Entyvio |
| Ironwood Pharmaceuticals, INC | $114.31 | 2019-2024 | Linzess |
| Lilly USA, LLC | $93.53 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $71.87 | 2024-2025 | |
| Ucb, INC. | $55.04 | 2019 | |
| Braintree Laboratories, INC. | $53.85 | 2019-2025 | Suflave |
| Qol Medical, LLC | $52.85 | 2024-2025 | Sucraid, Sucraid |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $51.68 | 2025 | Vegzelma |
| Pfizer INC. | $44.40 | 2023-2024 | |
| Aimmune Therapeutics, INC. | $44.37 | 2025 | Vowst |
| Fresenius Kabi USA, LLC | $43.94 | 2023-2024 | Idacio |
| Janssen Biotech, INC. | $40.61 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $36.99 | 2019-2023 | Dificid |
| Medtronic, INC. | $25.46 | 2023 | Endoflip |
| Redhill Biopharma INC. | $19.72 | 2021 | |
| Daiichi Sankyo INC. | $16.55 | 2019 | |
| Ferring Pharmaceuticals INC. | $16.23 | 2023 | Rebyota |
| Alfasigma USA, INC. | $12.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cribb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.